Kalvista Pharmaceuticals Inc at H C Wainwright Hereditary Angioedema (HAE) Conference (Virtual) Transcript
Hi, everyone. I'm Andrew Fein, one of the biotech analysts at H.C. Wainwright. Thank you very much for joining us on our HAE Day event. Next presenting will be KalVista. From KalVista, we have Andy, Chris and Ben, senior management team. So we can just dive right into it.
Questions & Answers
I mean it's been an interesting day from a physician perspective, I'd say. We've heard one major academician who was quite willing to switch patients from prophylactic treatment to acute treatment and didn't seem to have necessarily a lot of stickiness to any particular treatment; and another physician who was a bit stickier, I'd say, in terms of lack of willingness to perhaps shift patients if they're doing perfectly fine.
So I guess, Andy or any of you guys, how does that jibe with what you guys have diligence from
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |